Virtual Library

Start Your Search

Ulku Yilmaz



Author of

  • +

    EP1.04 - Immuno-oncology (ID 194)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Immuno-oncology
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.04-17 - The Association of Clinicopathologic Features and Peripheral Blood Parameters with High PD-L1 Expression in Non-Small Cell Lung Cancer (Now Available) (ID 2422)

      08:00 - 18:00  |  Author(s): Ulku Yilmaz

      • Abstract
      • Slides

      Background

      Programmed death ligand 1 (PD-L1) is a marker that widely used for prediction of response to immune check-point inhibitors (ICIs). Especially, PD-L1 tumor proportion score (TPS) of 50% or greater strongly predict the response of ICI in non-small cell lung cancer (NSCLC). However, dynamic alteration of PD-L1 expression are the major problems for reflection of the actual status of the PD-L1 expression level. Because of that, we aimed to investigate the factors that may be associated with PD-L1 TPS expression level for reflection of the actual status of PD-L1 TPS expression.

      Method

      The patients who diagnosed with NSCLC and known PD-L1 expression level at the diagnosis were enrolled to study. The data was collected as retrospectively. PD-L1 expression was assessed by using PD-L1 IHC 22C3 pharmDx assay. The patients were stratified according to PD-L1TPS expression level as ≥ 50% and < 50%. For detection of PD-L1 related factors, clinicopathologic features and peripheral blood parameters which were obtained at the diagnosis and before the initiation of any treatment was used. Neutrophil-lymphocyte ratio (NLR) and the platelet-lymphocyte ratio (PLR) were calculated and also systemic immune-inflammation index was calculated by using formula as follow: (Neutrophil x Platelets)/ Lymphocyte.

      Result

      Totally, 152 patients were enrolled to study. A hundred four of 152 patients (68.4%) were PD-L1 TPS expression level < 50% and 48 of 152 patients (31.6%) were also PD-L1 TPS expression level ≥ 50%.The clinicopathologic features were similar between TPS ≥ 50% and < 50% groups, except the amount of cigarette consumption. In univariate analyses; NLR, PLR, and SII were found significantly lower in patients with TPS ≥ 50% (p: 0.003 for NLR, p: 0.019 for PLR, p: 0.008 for SII).In correlation analyses NLR and PLR were found negatively correlated with PD-L1 TPS expression (r: -0.170, p:0.037 for NLR; r: -0.184, p: 0.024 for PLR).

      The association of PD-L1 TPS expression and peripheral blood parameters

      Parameter

      PD-L1 TPS < 50% (Median)

      PD-L1 TPS ≥ 50% (Median)

      p

      Hemoglobin (g/dl)

      12.95

      12.90

      0.54

      RDW

      14.7

      14.8

      0.37

      LDH (mg/dl)

      220

      218

      0.66

      CRP (mg/dl)

      7.8

      8.28

      0.88

      Albumin (mg/dl)

      3.9

      3.92

      0.62

      NLR

      3.96

      3.19

      0.003

      PLR

      177.8

      145.7

      0.019

      SII

      1253.1

      999.6

      0.008

      Conclusion

      According to the results of our study, NLR, PLR, and SII can be used to the prediction of the high PD-L1 expression level. In addition, NLR and PLR, easily accessible - assessable and also cheap markers, can be used for reflection of current PD-L1 expression status in the during the treatment with ICIs that targeted to PD-1/PD-L1.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.